Effects of Sorafenib on Intra-Tumoral Interstitial Fluid Pressure and Circulating Biomarkers in Patients with Refractory Sarcomas (NCI Protocol 6948)
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
PURPOSE: Sorafenib is a multi-targeted tyrosine kinase inhibitor with therapeutic efficacy in several malignancies. Sorafenib may exert its anti-neoplastic effect in part by altering vascular permeability and reducing intra-tumoral interstitial hypertension. As correlative science with a phase II study in patients with advanced soft-tissue sarcomas (STS), we evaluated the impact of this agent on intra-tumor interstitial fluid pressure (IFP), serum circulating biomarkers, and vascular density. PATIENTS AND METHODS: Patients with advanced STS with measurable disease and at least one superficial lesion amenable to biopsy received sorafenib 400 mg twice daily. Intratumoral IFP and plasma and circulating cell biomarkers were measured before and after 1-2 months of sorafenib administration. Results were analyzed in the context of the primary clinical endpoint of time-to-progression (TTP). RESULTS: In 15 patients accrued, the median TTP was 45 days (range 14-228). Intra-tumoral IFP measurements obtained in 6 patients at baseline showed a direct correlation with tumor size. Two patients with stable disease at two months had post-sorafenib IFP evaluations and demonstrated a decline in IFP and vascular density. Sorafenib significantly increased plasma VEGF, PlGF, and SDF1α and decreased sVEGFR-2 levels. Increased plasma SDF1α and decreased sVEGFR-2 levels on day 28 correlated with disease progression. CONCLUSIONS: Pretreatment intra-tumoral IFP correlated with tumor size and decreased in two evaluable patients with SD on sorafenib. Sorafenib also induced changes in circulating biomarkers consistent with expected VEGF pathway blockade, despite the lack of more striking clinical activity in this small series. TRIAL REGISTRATION: ClinicalTrials.gov NCT00330421.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
High Interstitial Fluid Pressure - an Obstacle in Cancer Therapy
Heldin, C.-H., Rubin, K., Pietras, K., & Östman, A. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1456 · Cited by 2,222 · cited 1×
“) may reduce tumor IFP, increase tumor uptake of chemotherapy agents, and enhance their therapeutic effects [21,22,23].”
BackgroundTong, R. T., Boucher, Y., Kozin, S. V., Winkler, F., Hicklin, D. J., & Jain, R. K. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0074 · Cited by 1,189 · cited 2×
“Antibody blockade of VEGFR-2 reduces both tumor vascular permeability and IFP and increases both the transvascular pressure gradient and penetration of small tracers into solid tumors [19,20].”
BackgroundSelf-citationBiomarkers of response and resistance to antiangiogenic therapy
Jain, R. K., Duda, D. G., Willett, C. G., Sahani, D. V., Zhu, A. X., Loeffler, J. S., Batchelor, T. T., & Sorensen, A. G. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.63 · Cited by 572
Self-citationBatchelor, T. T., Duda, D. G., di Tomaso, E., Ancukiewicz, M., Plotkin, S. R., Gerstner, E., Eichler, A. F., Drappatz, J., Hochberg, F. H., Benner, T., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3988 · Cited by 520 · cited 10×
“Kendall’s tb Pre-Treatment Size Response (SD) Radiographic Response Baseline IFP (N = 6)1 0.87 [0.56,1.17] 20.43 [20.91,0.05] 20.20 [20.63,0.23] P-value 0.017 0.40 0.82 Baseline IL-6 (N = 14)1 0.42 [0.10,0.74] 0.11 [20.23,0.45] 0.09 [20.36,0.54] P-value 0.037 0.70 0.74 Baseline PlGF (N = 14)1 0.31 [20.03,0.65] 20.39 […”
BackgroundInfluentialSelf-citationDuda, D. G., Cohen, K. S., Scadden, D. T., & Jain, R. K. (2007) · Nature Protocols · doi:10.1038/nprot.2007.111 · Cited by 275
Self-citationNathan, S. S., DiResta, G. R., Casas-Ganem, J. E., Hoang, B. H., Sowers, R., Yang, R., Huvos, A. G., Gorlick, R., & Healey, J. H. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2048 · Cited by 85 · cited 1×
“Studies from our group and others have shown that the intratumoral interstitial fluid pressure (IFP) in human sarcomas, melanomas, and carcinomas (including colon, breast, lung, head and neck, cervix) is significantly higher than in normal tissues [5,6,7,8,9,10,11,12,13,14,15,16,17].”
Background
Cited by
Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
Jain, R. K. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.006 · Cited by 1,589
“…elevated levels of sVEGFR1 prior to treatment were associatedwith a poor outcome frombevacizumab in rectal carcinoma, hepatocellular carcinoma (HCC), and metastatic colorectal carcinoma patients (Duda et al., 2010; Meyerhardt et al., 2012; Raut et al., 2012; Willett et al., 2009; Zhu et al., 2013).”
BackgroundSelf-citationNormalizing Tumor Microenvironment to Treat Cancer: Bench to Bedside to Biomarkers
Jain, R. K. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.3653 · Cited by 1,248
Self-citationBatchelor, T. T., Gerstner, E. R., Emblem, K. E., Duda, D. G., Kalpathy-Cramer, J., Snuderl, M., Ancukiewicz, M., Polaskova, P., Pinho, M. C., Jennings, D., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1318022110 · Cited by 340
Self-citationTolaney, S. M., Boucher, Y., Duda, D. G., Martin, J. D., Seano, G., Ancukiewicz, M., Barry, W. T., Goel, S., Lahdenrata, J., Isakoff, S. J., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1518808112 · Cited by 258
Self-citationHeist, R. S., Duda, D. G., Sahani, D. V., Ancukiewicz, M., Fidias, P., Sequist, L. V., Temel, J. S., Shaw, A. T., Pennell, N. A., Neal, J. W., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1424024112 · Cited by 126
Self-citation
Metadata
- Authors
- Raut, C. P., Boucher, Y., Duda, D. G., Morgan, J. A., Quek, R., Ancukiewicz, M., Lahdenranta, J., Eder, J. P., Demetri, G. D., & Jain, R. K.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-02-07
- Volume
- 7
- Issue
- 2
- Pages
- e26331
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2127452722
- Cited by
- 42
- References
- 6
- FWCI
- 6.40
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of Sorafenib on Intra-Tumoral Interstitial Fluid Pressure and Circulating Biomarkers in Patients with Refractory Sarcomas (NCI Protocol 6948). https://app.cochat.ai/papers/10.1371/journal.pone.0026331
- The paper
- Raut, C. P., Boucher, Y., Duda, D. G., Morgan, J. A., Quek, R., Ancukiewicz, M., Lahdenranta, J., Eder, J. P., Demetri, G. D., & Jain, R. K. (2012). Effects of Sorafenib on Intra-Tumoral Interstitial Fluid Pressure and Circulating Biomarkers in Patients with Refractory Sarcomas (NCI Protocol 6948). PLoS ONE. https://doi.org/10.1371/journal.pone.0026331
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.